Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T22:17:39.739Z.
Calculation as of: 2026-10-06T22:17:39.739Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 880fb47a961da82dee7b372bf013e19f9356fddf046c7e26e64914405e113cb3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Lexeo Therapeutics, Inc. Common Stock
Market Cap
$259.12M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.14M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.49M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.56M
EV/FCF Ratio
N/A
TTM Avg
0.65x
3Y Avg
2.46x
5Y Avg
493.92x
Market Cap
$261.43M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$255.88M
EV/FCF Ratio
428.44x
TTM Avg
210.95x
3Y Avg
227.91x
5Y Avg
182.13x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $259.12M | N/A | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | N/A | N/A | N/A | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $259.49M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | N/A | 0.65x | 2.46x | 493.92x |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | N/A | N/A | N/A | N/A |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $256.47M | N/A | 4.58x | 4.76x | 4.76x |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.88M | 428.44x | 210.95x | 227.91x | 182.13x |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
